Explore the words cloud of the RespiriNTM project. It provides you a very rough idea of what is the project "RespiriNTM" about.
The following table provides information about the project.
ACADEMISCH ZIEKENHUIS LEIDEN
|Coordinator Country||Netherlands [NL]|
|Total cost||8˙060˙640 €|
|EC max contribution||5˙687˙983 € (71%)|
1. H2020-EU.3.1.7. (Innovative Medicines Initiative 2 (IMI2))
|Duration (year-month-day)||from 2019-05-01 to 2025-04-30|
Take a look of project's partnership.
|1||ACADEMISCH ZIEKENHUIS LEIDEN||NL (LEIDEN)||coordinator||1˙570˙226.00|
|2||UNIVERSITEIT ANTWERPEN||BE (ANTWERPEN)||participant||1˙191˙325.00|
|3||MEDIZINISCHE UNIVERSITAET WIEN||AT (WIEN)||participant||848˙750.00|
|4||UNIVERSITEIT LEIDEN||NL (LEIDEN)||participant||766˙250.00|
|5||SORBONNE UNIVERSITE||FR (PARIS)||participant||726˙750.00|
|6||KOBENHAVNS UNIVERSITET||DK (KOBENHAVN)||participant||260˙067.00|
|7||FFUND BV||NL (AMSTERDAM)||participant||171˙555.00|
|9||JANSSEN PHARMACEUTICA NV||BE (BEERSE)||participant||0.00|
Non-tuberculous mycobacteria, such as Mycobacterium avium complex (MAC) and Mycobacterium abscessus, cause lung diseases resembling TB, mainly in immune-compromised patients or patients suffering from other lung diseases (e.g. cystic fibrosis). The incidence and prevalence of lung diseases caused by NTM are increasing worldwide. Importantly, in the US and Japan, as well as in other areas of the world where TB has declined, NTM disease is already at least three times more prevalent than TB. Treatment of NTM diseases relies on antibiotic combinations, however the drugs active against NTM are rather few and mainly different than those active against TB. These NTM treatments for the most common species (MAC and M. abscessus) are much less active than the current anti-TB regimen is for TB treatment. It is often necessary to administer antibiotic combinations for at least 12-24 months. The long and complex drug regimen that is currently recommended as a treatment against NTM-caused diseases carries the risk of inducing resistance in NTM. Several studies have already shown the existence and emergence of multidrug resistant NTM. The overall objective of RESPIRI-NTM is to find new drug candidates as potential components of a new, more efficient combination drug regimen against NTM that is less prone to resistance and allows shortening of treatment duration for NTM and multidrug-resistant NTM. Such a drug combination will synergistically target the energy metabolism of NTM or complementary targets. To achieve this, we will advance recently discovered inhibitors of the mycobacterial respiratory pathway. In addition, we will perform a novel, phenotypic screen in order to identify novel targets in NTM. Finally, we will also target host-factors that are essential for the intracellular survival of NTM. Together, we present a comprehensive plan to find novel strategies to combat non-tuberculous mycobacteria, shorten treatment time and reduce chances of drug resistance.
|Website RESPIRI- NTM online||Websites, patent fillings, videos etc.||2020-04-11 04:52:06|
Take a look to the deliverables list in detail: detailed list of RespiriNTM deliverables.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "RESPIRINTM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "RESPIRINTM" are provided by the European Opendata Portal: CORDIS opendata.
Progress novel assets (one FIH start) for non-tubercular mycobacteria that may act synergistically with bedaquiline and cytochrome bc drugsRead More
Bringing a prophylactic Ebola vaccine to licensureRead More
Parkinson Disease with Mild cognition Impairment treated with Nicotinic agonist DrugRead More